User login
An army of new drugs has transformed chronic myeloid leukemia from a fatal disease to a chronic condition. In this interview at the annual meeting of the American Society of Hematology, Dr. Elias Jabbour of M.D. Anderson Cancer Center discusses choices clinicians face in CML therapy -- and what he sees as the next step in eradicating the disease.
An army of new drugs has transformed chronic myeloid leukemia from a fatal disease to a chronic condition. In this interview at the annual meeting of the American Society of Hematology, Dr. Elias Jabbour of M.D. Anderson Cancer Center discusses choices clinicians face in CML therapy -- and what he sees as the next step in eradicating the disease.
An army of new drugs has transformed chronic myeloid leukemia from a fatal disease to a chronic condition. In this interview at the annual meeting of the American Society of Hematology, Dr. Elias Jabbour of M.D. Anderson Cancer Center discusses choices clinicians face in CML therapy -- and what he sees as the next step in eradicating the disease.
